Texas
|
75-1974352
|
(State
of
other jurisdiction of
|
(I.R.S.
Employer
|
incorporation
or organization)
|
Identification
No.)
|
4134
Business Park Drive, Amarillo, Texas
|
79110-4225
|
(Address
of
principal executive offices)
|
(Zip
Code)
|
1. |
Item
8A has
been changed to state that the Company’s accounting firm has not issued an
attestation report on the management’s assessment of internal
controls;
|
2. |
the
Report of
Independent Registered Public Accounting Firm has been changed
to state
that the Company’s recurring losses and need to raise additional funds
raise substantial doubt about the Company’s ability to continue as a going
concern; and
|
3. |
the
Notes to
the Consolidated Financial Statements include additional and expanded
disclosure of our accounting policies regarding research grant
revenue,
stock options granted to non-employees, and related party
transactions.
|
2005
|
2004
|
|||
Quarter
|
High
|
Low
|
High
|
Low
|
First
|
$0.58
|
$0.29
|
$0.44
|
$0.27
|
Second
|
0.45
|
0.31
|
0.35
|
0.18
|
Third
|
0.38
|
0.27
|
0.32
|
0.20
|
Fourth
|
0.61
|
0.27
|
0.38
|
0.21
|
Shares
repurchased from the Crowe Estate:
|
120
shares
|
Name
|
Age
|
Position
|
Joseph
Cummins, DVM, PhD (1)(3)
|
63
|
Chairman
of
the Board, President,
|
Chief
Executive Officer, Chief
|
||
Financial
Officer and Director
|
||
Stephen
Chen,
PhD (2)(4)
|
56
|
Director
|
Katsuaki
Hayashibara (3)(4)(5)
|
61
|
Director
|
Dennis
Moore,
DVM (1)(4)(5)
|
59
|
Director
|
James
Page,
MD (1)(2)(5)
|
78
|
Director
|
Martin
J
Cummins
|
38
|
Director
of
Clinical & Regulatory Affairs
|
(1)
|
Member
of the Executive Committee.
|
(2)
|
Member
of the Compensation Committee.
|
(3)
|
Member
of the Finance Committee.
|
(4)
|
Member
of the Audit Committee.
|
(5) | Member of the Stock Option Plans Administration Committee |
Annual
Compensation
|
Long
Term Compensation
|
||||
Name
and Principal Position
|
Year
|
Salary
|
Bonus
|
Other
Compensation
|
Securities
Underlying Options
|
Dr.
Joseph M.
Cummins, Chairman of the Board, President and Chief Executive
Officer
|
2005
|
$
177,000
|
$
-
|
$
-
|
600,000
|
2004
|
$
74,716
|
$
-
|
$
-
|
650,000
|
|
2003
|
$
103,779
|
$
-
|
$
-
|
490,000
|
Name
|
Number
of Shares of Common Stock Underlying Options Granted
(#)
|
%
of
Total Options Granted to Employees in 2005
|
Exercise
or Base Price ($/Sh)
|
Expiration
Date
|
Joseph
M.
Cummins
|
100,000
|
7.7%
|
$0.40
(1)
|
02/25/2010
|
500,000
|
38.5%
|
$0.30
(1)
|
08/22/2010
|
(1) |
The
fair market value of the common stock on the date of the
grant.
|
Name
|
Shares
Acquired on Exercise (#)
|
Value
Realized ($)
|
Number
of Shares of Common Stock Underlying Unexercised Options
at
December
31, 2005 (#) Exercisable/Unexercisable
|
Value
of Unexercised In-The-Money Options at December 31, 2005 ($) (1)
Exercisable/Unexercisable
|
||
Joseph
Cummins
|
--
|
--
|
1,788,486
|
None
|
$769,049
|
None
|
(1) |
Calculated
based on the closing price of the common stock ($0.43) as reported
by OTC
BB on December 30, 2005.
|
Cash
Compensation
|
Stock
Options
|
||
Name
|
Meeting
Fees (1)
|
Consulting
Fees (2)
|
Number
of Securities Underlying Options
|
Stephen
Chen,
PhD
|
$
--
|
$
--
|
600,000
|
Katsuaki
Hayashibara
|
--
|
--
|
600,000
|
Dennis
Moore,
DVM
|
--
|
--
|
600,000
|
James
Page,
MD
|
--
|
--
|
600,000
|
(2)
|
Directors
may receive up to $1,200 per day, prorated for partial days, for
employment on special projects or
assignments.
|
Name
and Address
|
Amount
and Nature of Beneficial Ownership
|
Percent
of Class Owned
|
Hayashibara
Biochemical Laboratories, Inc.
|
||
2-3
Shimoishii 1-chome
|
||
Okayama
700,
Japan
|
3,290,781
|
17%
|
Name
and Address of Owner
|
Amount
and Nature of Beneficial Ownership
|
Percent
of Class Owned
|
Joseph
Cummins
2122
Harrison
Amarillo,
TX
79109
|
2,025,0321
|
9.4%
|
Dennis
Moore
402
Fish
Hatchery
Hamilton,
MT
59840
|
864,2992
|
4.2%
|
Katsuaki
Hayashibara
2-3,
Shimoishii, 1-chome
Okayama,
700
Japan
|
912,3653
|
4.4%
|
Stephen
Chen
Floor
7-1,
No. 18
Xin
Yi Road,
Sec. 5
Taipei,
Taiwan
|
864,1254
|
4.2%
|
James
Page
103
Clubhouse
Lane, #182
Naples,
FL
34105
|
864,1255
|
4.2%
|
Total
Group
(all directors and executive officers - 5 persons)
|
5,529,946
|
22.2%
|
3.1†
|
Restated
Articles of Incorporation of the Company, dated June 22,
1999.
|
3.3*
|
Bylaws
of the
Company.
|
4.1*
|
Specimen
Common Stock Certificate.
|
4.2*
|
Form
of
Underwriter's Warrant.
|
10.2*
|
License
Agreement dated as of March 22, 1988 between the Company and The
Texas
A&M University System.
|
10.5*
|
Joint
Development and Manufacturing/Supply Agreement dated March 13, 1992
between the Company and HBL, as amended.
|
10.7*
|
Japan
Animal
Health License Agreement dated January 20, 1993 between the Company
and
HBL.
|
10.11*
|
Manufacturing/Supply
Agreement dated June 1, 1994 between the Company and
HBL.
|
10.12*
|
Settlement
Agreement dated April 27, 1995 among the Company, ISI, Pharma Pacific
Management Pty. Ltd. ("PPM"), Pharma Pacific Pty. Ltd., Pharma Pacific
Ltd. and Fernz Corporation Limited.
|
10.14*
|
PPM/ACC
Sublicense Agreement dated April 27, 1995 between PPM and the
Company.
|
10.18*
|
Form
of
Consulting Agreement between the Company and the
Underwriter.
|
10.20†
|
1996
Employee
Stock Option Plan, Amended and Restated as of May 11,
1999.
|
10.21†
|
Outside
Director and Advisor Stock Option Plan, Amended and Restated as of
May 11,
1999.
|
10.22*
|
Form
of
Indemnification Agreement between the Company and officers and directors
of the Company.
|
10.23*
|
Indemnification
Agreement between HBL and the Company.
|
10.26**
|
License
Agreement dated July 22, 1997 between Hoffmann-La Roche, Inc. and
the
Company.
|
10.27**
|
Distribution
Agreement dated January 12, 1998 between Global Damon Pharmaceutical
and
the Company.
|
10.28**
|
Distribution
Agreement dated September 17, 1997 between HBL and the Company (tumor
necrosis factor-alpha).
|
10.29**
|
Distribution
Agreement dated September 17, 1997 between HBL and the Company (interferon
gamma).
|
10.30***
|
Amendment
No.
1 dated September 28, 1998 to License Agreement of March 22, 1988
between
The Texas A&M University System and the Company.
|
10.36††
|
License
Agreement dated February 1, 2000 between Molecular Medicine Research
Institute and the Company (interferon gamma administered
orally).
|
10.37††
a
|
License
and
Supply Agreement dated April 3, 2000 with Key Oncologics (Pty) Ltd.
and
the Company.
|
|
10.38††
|
Amendment
No.
1 dated April 4, 2000, to Interferon Gamma Distribution Agreement
dated
September 17, 1997 between HBL and the Company (interferon
gamma).
|
|
10.39††
a
|
License
and
Supply Agreement dated April 25, 2000 between Biopharm for Scientific
Research and Drug Industry Development and the Company.
|
|
10.40††
a
|
Sales
Agreement dated May 5, 2000 between Wilke Resources, Inc. and the
Company.
|
|
10.41††
|
Engagement
Agreement dated September 26, 2000 between Hunter Wise Financial
Group,
LLC and the Company.
|
|
10.42††
a
|
Supply
Agreement (Anhydrous Crystalline Maltose) dated October 13, 2000
between
Hayashibara Biochemical Laboratories, Inc. and the
Company.
|
|
10.43††
a
|
Supply
Agreement dated December 11, 2000 between Natrol, Inc. and the
Company.
|
|
10.44†††
a
|
License
Agreement dated September 7, 2001 between Atrix Laboratories, Inc.
and the
Company.
|
|
10.45††††
a
|
Supply
Agreement dated June 20, 2004 between Global Kinetics, Inc. and the
Company.
|
|
10.46††††
a
|
License
and
Supply Agreement dated September 13, 2004 between Nobel ILAC SANAYII
VE
TICARET A.S. and the Company.
|
|
10.47
a
|
License
and
Supply Agreement dated October 19, 2005 between Global Kinetics,
Inc. and
the Company.
|
|
10.48
a
|
License
and
Supply Agreement dated January 18, 2006, between Bumimedic (Malaysia)
SDN.
BHD., and the Company.
|
|
21.
|
Subsidiaries
of the Company. The following sets forth the name and jurisdiction
of
incorporation of each subsidiary of the Company. All of such subsidiaries
are wholly-owned by the Company.
|
|
Name
|
Jurisdiction
of Incorporation
|
|
Vanguard
Biosciences, Inc.
|
Texas
|
|
Veldona
Africa, Inc.
|
Texas
|
|
Veldona
Poland, Inc.
|
Texas
|
|
ABI
Taiwan, Inc.
|
Texas
|
|
Amarillo
Cell of Canada, Inc.
|
Texas
|
Audit
Fees
|
|||
2005
|
2004
|
||
Malone
& Bailey, PLLC
|
$15,000
|
||
Lopez,
Blevins, Bork & Assoc. LLP
|
$17,875
|
$
3,500
|
Audit-Related
Fees
|
|||
2005
|
2004
|
||
Johnson
& Sheldon
|
$465
|
$575
|
Tax
Fees
|
|||
2005
|
2004
|
||
Johnson
& Sheldon
|
$2,750
|
$2,100
|
AMARILLO
BIOSCIENCES, INC.
|
|
Date:
January 3,
2007
|
By:
/s/
Joseph M.
Cummins
Joseph
M.
Cummins, Chairman of the Board, President, and Chief Executive Officer
|
Date: January 3, 2007 |
By:
/s/ Gary
Coy
Gary
Coy, Vice
President and Chief Financial
Officer
|
Signature
|
Title
|
Date
|
|
/s/
Joseph M.
Cummins
|
Chairman of the Board, President, Director and Chief Executive Officer |
January
3,
2007
|
|
Joseph M. Cummins | |||
/s/
Stephen
T. Chen
|
Director
|
January
3,
2007
|
|
Stephen
T.
Chen
|
|||
/s/
James A.
Page
|
Director
|
January
3,
2007
|
|
James
A.
Page
|
|||
/s/
Dennis
Moore
|
Director
|
January
3,
2007
|
|
Dennis
Moore
|
|||
Thomas
D'Alonzo
|
Director
|
|
|
Thomas
Ulie
|
Director |
|
Report
of
Independent Registered Public Accounting Firm
|
F-1
|
Audited
Consolidated Financial Statements
|
|
Consolidated
Balance Sheet
|
F-2
|
Consolidated
Statements of Operations
|
F-3
|
Consolidated
Statements of Stockholders’ Deficit
|
F-4
|
Consolidated
Statements of Cash Flows
|
F-5
|
Notes
to
Consolidated Financial Statements
|
F-6
|
Assets
|
||||
Current
assets:
|
||||
Cash
|
$
|
193,315
|
||
Other current assets
|
2,788
|
|||
Total
current assets
|
196,103
|
|||
Equipment,
net
|
725
|
|||
Patents,
net of accumulated amortization of $191,789
|
118,907
|
|||
Total
assets
|
$
|
315,735
|
||
Liabilities
and Stockholders' Deficit
|
||||
Current
liabilities:
|
||||
Accounts payable
|
$
|
41,513
|
||
Accrued interest expense
|
510,701
|
|||
Notes payable, including notes payable to stockholder
|
2,093,500
|
|||
Total
current liabilities
|
2,645,714
|
|||
Total
Liabilities
|
2,645,714
|
|||
Commitments
and contingencies
|
||||
Stockholders'
deficit
|
||||
Preferred stock, $.01 par value:
|
||||
Authorized shares - 10,000,000
|
||||
Issued shares - none
|
-
|
|||
Common stock, $.01par value:
|
||||
Authorized shares - 50,000,000
|
||||
Issued shares - 19,801,870
|
198,019
|
|||
Additional paid-in capital
|
20,648,219
|
|||
Accumulated deficit
|
(23,176,217
|
)
|
||
Total
stockholders' deficit
|
(2,329,979
|
)
|
||
Total
liabilities and stockholder's deficit
|
$
|
315,735
|
||
|
Years
ended December 31,
|
||||||
2005
|
2004
|
||||||
Revenues:
|
|||||||
Dietary supplement sales
|
$
|
42,730
|
$
|
35,899
|
|||
Interferon sales
|
-
|
9,490
|
|||||
Federal research grant
|
44,349
|
-
|
|||||
Royalty revenue
|
67,486
|
-
|
|||||
Other
|
-
|
6,117
|
|||||
Total
Revenues
|
154,565
|
51,506
|
|||||
Expenses:
|
|||||||
Cost of sales
|
22,456
|
14,949
|
|||||
Research and development expenses
|
187,810
|
171,043
|
|||||
Selling, general and administrative expenses
|
492,659
|
362,388
|
|||||
Interest expense
|
120,651
|
98,331
|
|||||
Total
Expenses
|
823,576
|
646,711
|
|||||
Net
income (loss)
|
$
|
(669,011
|
)
|
$
|
(595,205
|
)
|
|
Basic
and diluted net income (loss) per share
|
$
|
(0.04
|
)
|
$
|
(0.05
|
)
|
|
Weighted
average shares outstanding
|
16,495,678
|
12,446,690
|
|||||
|
Common
Stock
|
Additional
Paid in Capital
|
Accumulated
Deficit
|
Total
Stockholders' Deficit
|
|||||||||||||||
|
Issuance
Price
|
Shares
|
Amount
|
|
|||||||||||||||
Balance
at December 31, 2003
|
11,060,017
|
$
|
110,600
|
$
|
19,279,417
|
$
|
(21,912,001
|
)
|
$
|
(2,521,984
|
)
|
||||||||
Net
loss for year ended December 31, 2004
|
-
|
-
|
-
|
(595,205
|
)
|
(595,205
|
)
|
||||||||||||
Issuance
of common stock for services
|
0.2033-0.350
|
47,380
|
474
|
13,486
|
-
|
13,960
|
|||||||||||||
Issuance
of common stock for cash in private placements
|
0.10-0.13
|
2,576,385
|
25,764
|
245,166
|
-
|
270,930
|
|||||||||||||
Issuance
of common stock for debt
|
0.37
|
100,000
|
1,000
|
36,000
|
-
|
37,000
|
|||||||||||||
Exercise
of options for service
|
0.20-0.21
|
450,000
|
4,500
|
87,500
|
-
|
92,000
|
|||||||||||||
Exercise
of options for cash
|
0.06
|
151,514
|
1,515
|
7,576
|
-
|
9,091
|
|||||||||||||
Balance
at December 31, 2004
|
14,385,296
|
143,853
|
19,669,145
|
(22,507,206
|
)
|
(2,694,208
|
)
|
||||||||||||
Net
loss for year ended December 31, 2005
|
-
|
-
|
-
|
(669,011
|
)
|
(669,011
|
)
|
||||||||||||
Issuance
of common stock for services
|
0.29-0.4467
|
37,994
|
380
|
12,832
|
-
|
13,212
|
|||||||||||||
Issuance
of common stock for cash in private placements
|
0.20-0.22
|
4,928,700
|
49,287
|
800,702
|
-
|
849,989
|
|||||||||||||
Exercise
of options for service
|
0.32-0.35
|
450,000
|
4,500
|
145,500
|
-
|
150,000
|
|||||||||||||
Issuance
of warrants in connection with debt
|
-
|
-
|
20,105
|
-
|
20,105
|
||||||||||||||
Purchase
and retirement of common stock
|
0.55
|
(120
|
)
|
(1
|
)
|
(65
|
)
|
(66
|
)
|
||||||||||
Balance
at December 31, 2005
|
19,801,870
|
$
|
198,019
|
$
|
20,648,219
|
$
|
(23,176,217
|
)
|
$
|
(2,329,979
|
)
|
||||||||
|
Years
ended December 31,
|
||||||
Operating
Activities
|
2005
|
2004
|
|||||
Net
income (loss)
|
$
|
(669,011
|
)
|
$
|
(595,205
|
)
|
|
Adjustments
to reconcile net income (loss) to net cash provided by (used
for)
operating activities:
|
|||||||
Depreciation and amortization
|
12,439
|
29,041
|
|||||
Common stock issued for services
|
150,712
|
105,960
|
|||||
Issuance
of warrants in connection with debt
|
20,105
|
||||||
Changes in operating assets and liabilities:
|
|||||||
Other current assets
|
(1,953
|
)
|
4,737
|
||||
Accounts payable
|
(120,381
|
)
|
18,490
|
||||
Accrued expenses
|
(47,302
|
)
|
108,925
|
||||
Net
cash used in operating activities
|
(655,391
|
)
|
(328,052
|
)
|
|||
Investing
Activities
|
|||||||
Patents
|
-
|
(3,486
|
)
|
||||
Net
cash provided by (used in) investing activities
|
-
|
(3,486
|
)
|
||||
Financing
Activities
|
|||||||
Proceeds
from notes payable
|
-
|
20,000
|
|||||
Proceeds
from excersise of options
|
12,500
|
-
|
|||||
Repayments
of notes payable
|
(20,000
|
)
|
(10,500
|
)
|
|||
Purchase
and retirement of common stock
|
(66
|
)
|
-
|
||||
Issuance
of common stock
|
849,989
|
317,021
|
|||||
Net
cash provided by financing activities
|
842,423
|
326,521
|
|||||
Net
increase (decrease) in cash
|
187,032
|
(5,017
|
)
|
||||
Cash
at beginning of period
|
6,283
|
11,300
|
|||||
Cash
at end of period
|
$
|
193,315
|
$
|
6,283
|
|||
Supplemental
Cash Flow Information
|
|||||||
Cash
paid for interest
|
$
|
36,967
|
$
|
5,542
|
|||
|
For
the Year Ended December 31,
|
||||||
2005
|
2004
|
||||||
Net loss, as reported
|
$
|
(625,186
|
)
|
$
|
(595,205
|
)
|
|
Less: stock based compensation determined
under fair value based method
|
$
|
(984,339
|
)
|
$
|
(360,199
|
)
|
|
Pro forma net loss
|
$
|
(1,609,525
|
)
|
$
|
(955,404
|
)
|
|
Basic and diluted net loss per share
|
|||||||
As reported
|
$
|
(0.04
|
)
|
$
|
(0.05
|
)
|
|
Pro forma
|
$
|
(0.10
|
)
|
$
|
(0.08
|
)
|
|
December
31,
2005
|
|||
Furniture
and
equipment
|
$
|
54,011
|
||
54,011
|
||||
Less
accumulated depreciation
|
53,286
|
|||
$
|
725
|
2005
|
2004
|
||||||||||||
|
Options
|
Price
|
Options
|
Price
|
|||||||||
Outstanding
Beg of Year
|
2,925,862
|
0.41
|
2,071,688
|
0.54
|
|||||||||
Granted
|
3,920,000
|
0.31
|
1,500,000
|
0.25
|
|||||||||
Cancelled
|
-
|
(494,312
|
)
|
1.12
|
|||||||||
Exercised
|
-
|
(151,514
|
)
|
0.06
|
|||||||||
Outstanding
End of Year
|
6,845,862
|
0.31
|
2,925,862
|
0.41
|
|||||||||
Exercisable
End of Year
|
6,845,862
|
0.31
|
2,925,862
|
0.41
|